Patisiran continued to demonstrate benefit in hATTR with polyneuropathy at 5 years. Measures of disability, polyneuropathy, and quality of life showed modest changes. This is the longest study of an ...
Please provide your email address to receive an email when new articles are posted on . Wainua has received regulatory approval for polyneuropathy of hereditary transthyretin-mediated amyloidosis.
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Ionis’ WAINUA™ (eplontersen) has been approved in the US for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in ...
Eplontersen (Wainua) was approved by the FDA to treat polyneuropathy associated with hereditary transthyretin-mediated amyloidosis (ATTR) in adults, Ionis Pharmaceuticals and AstraZeneca announced on ...
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed ...
Hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) can affect many parts of the body. Nerve symptoms are often the earliest signs of this condition. hATTR-PN is a rare genetic ...
Living with hATTR-PN can be challenging, both physically and emotionally. However, multiple resources can offer treatment support, financial help, and ways to connect with others. Hereditary ...
– AMVUTTRA Met Primary and All Secondary Endpoints, with Significant Improvement in Polyneuropathy, Quality of Life and Gait Speed Relative to External Placebo – – Company Expects to Launch in Early ...
Credit: Getty Images. Eplontersen is an investigational ligand-conjugated antisense medicine. The Food and Drug Administration (FDA) has accepted for review the New Drug Application for eplontersen ...
The investigational agent eplontersen (Ionis Pharmaceuticals/AstraZeneca) halted neuropathy disease progression and improved neuropathy impairment and quality of life ...
Wainua is supplied in a carton containing one 45mg/0.8mL single-dose autoinjector; it is expected to be available in January 2024. The Food and Drug Administration (FDA) has approved Wainua™ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results